Acetylation in the regulation of metalloproteinase and tissue inhibitor of metalloproteinases gene expression

Frontiers in Bioscience

Volumn 12, Issue 2, 2007, Pages 528-535

  Clark, Ian M ^a   Swingler, Tracey E ^a   Young, David A ^b  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Acetylation; AP1; c Jun; HDAC; Metalloproteinase; MMP; NF B; Review; Smad; STAT; Trichostatin A

Indexed keywords

EID: 33846693285     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/2079     Document Type: Article

References (58)

1. Egeblad, M. & Z. Werb: New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer, 2, 161-174 (2002)
2. Chakraborti, S., M. Mandal, S. Das, A. Mandal & T. Chakraborti: Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem, 253, 269-285 (2003)
3. Wolffe, A. P. & D. Guschin: Review: chromatin structural features and targets that regulate transcription. J Struct Biol, 129, 102-122 (2000)
4. Narlikar, G. J., H. Y. Fan & R. E. Kingston: Cooperation between complexes that regulate chromatin structure and transcription. Cell, 108, 475-487 (2002)
5. Sudarsanam, P. & F. Winston: The Swi/Snf family nucleosome-remodeling complexes and transcriptional control. Trends Genet, 16, 345-351 (2000)
6. Berger, S. L.: Histone modifications in transcriptional regulation. Curr Opin Genet Dev, 12, 142-148 (2002)
7. Clayton, A. L., S. Rose, M. J. Barratt & L. C. Mahadevan: Phosphoacetylation of histone H3 on c-fos- and c-jun-associated nucleosomes upon gene activation. EMBO J, 19, 3714-3726 (2000)
8. Kouzarides, T.: Acetylation: a regulatory modification to rival phosphorylation? EMBO J, 19, 1176-1179 (2000)
9. de Ruijter, A. J., A. H. van Gennip, H. N. Caron, S. Kemp & A. B. van Kuilenburg: Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J, 370, 737-749 (2003)
10. Gao, L., M. A. Cueto, F. Asselbergs & P. Atadja: Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem, 277, 5748-25755 (2002)
11. Ng, H. H. & A. Bird: Histone deacetylases: silencers for hire. Trends Biochem Sci, 25, 121-126 (2000)
12. Yuan, Z. L., Y. J. Guan, D. Chatterjee & Y. E. Chin: Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science, 307, 269-273 (2005)
13. Yang, X. J. & S. Gregoire: Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol, 25, 2873-2884 (2005)
14. Quivy, V. & C. Van Lint: Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem Pharmacol, 68, 1221-1229 (2004)
15. Vries, R. G., M. Prudenziati, C. Zwartjes, M. Verlaan, E. Kalkhoven & A. Zantema: A specific lysine in c-Jun is required for transcriptional repression by E1A and is acetylated by p300. EMBO J, 20, 6095-6103 (2001)
16. Gu, W. & R. G. Roeder: Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell, 90, 595-606 (1997)
17. Gregoretti, I. V., Y. M. Lee & H. V. Goodson: Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol, 338, 17-31 (2004)
18. Yoshida, M., M. Kijima, M. Akita & T. Beppu: Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem, 265, 17174-17179 (1990)
19. Kruh, J.: Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem, 42, 65-82 (1982)
20. Bernstein, B. E., J. K. Tong & S. L. Schreiber: Genomewide studies of histone deacetylase function in yeast. Proc Natl Acad Sci USA, 97, 13708-13713 (2000)
21. Mulholland, N. M., E. Soeth & C. L. Smith: Inhibition of MMTV transcription by HDAC inhibitors occurs independent of changes in chromatin remodeling and increased histone acetylation. Oncogene, 22, 4807-4818 (2003)
22. Nair, A. R., L. J. Boersma, L. Schiltz, M. A. Chaudhry, R. J. Muschel & A. Chaudry: Paradoxical effects of trichostatin A: inhibition of NF-Y-associated histone acetyltransferase activity, phosphorylation of hGCN5 and downregulation of cyclin A and B1 mRNA. Cancer Lett, 166, 55-64 (2001)
23. Pujuguet, P., D. Radisky, D. Levy, C. Lacza & M. J. Bissell: Trichostatin A inhibits beta-casein expression in mammary epithelial cells. J Cell Biochem, 83, 660-670 (2001)
24. Saunders, N., A. Dicker, C. Popa, S. Jones & A. Dahler: Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res, 59, 399-404 (1999)
25. Peart, M. J., G. K. Smyth, R. K. van Laar, D. D. Bowtell, V. M. Richon, P. A. Marks, A. J. Holloway & R. W. Johnstone: Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci USA, 102, 3697-3702 (2005)
26. Weidle, U. H. & A. Grossmann: Inhibition of histone deacetylases: a new strategy to target epigenetic modifications for anticancer treatment. Anticancer Res, 20, 1471-1485 (2000)
27. Chambers, A. E., S. Banerjee, T. Chaplin, J. Dunne, S. Debernardi, S. P. Joel & B. D. Young: Histone acetylation-mediated regulation of genes in leukaemic cells. Eur J Cancer, 39, 1165-1175 (2003)
28. Johnstone, R. W.: Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov, 1, 287-299 (2002)
29. Monneret, C.: Histone deacetylase inhibitors. Eur J Med Chem, 40, 1-13 (2005)
30. Gottlicher, M.: Valproic acid: an old drug newly discovered as inhibitor of histone deacetylases. Ann Hematol, 83 Suppl 1, S91-92 (2004)
31. Pender, S. L., J. J. Quinn, I. R. Sanderson & T. T. MacDonald: Butyrate upregulates stromelysin-1 production by intestinal mesenchymal cells. Am J Physiol Gastrointest Liver Physiol, 279, G918-924 (2000)
32. Ailenberg, M. & M. Silverman: Trichostatin A-histone deacetylase inhibitor with clinical therapeutic potential-is also a selective and potent inhibitor of gelatinase A expression. Biochem Biophys Res Commun, 298, 110-115 (2002)
33. Ailenberg, M. & M. Silverman: Differential effects of trichostatin A on gelatinase A expression in 3T3 fibroblasts and HT-1080 fibrosarcoma cells: implications for use of ISA in cancer therapy. Biochem Biophys Res Commun, 302, 181-185 (2003)
34. Kaneko, F., H. Saito, Y. Saito, K. Wakabayashi, N. Nakamoto, S. Tada, H. Suzuki, S. Tsunematsu, N. Kumagai & H. Ishii: Down-regulation of matrix-invasive potential of human liver cancer cells by type I interferon and a histone deacetylase inhibitor sodium butyrate. Int J Oncol, 24, 837-845 (2004)
35. Thelen, P., S. Schweyer, B. Hemmerlein, W. Wuttke, F. Seseke & R. H. Ringert: Expressional changes after histone deacetylase inhibition by valproic acid in LNCaP human prostate cancer cells. Int J Oncol, 24, 25-31 (2004)
36. Martens, J. H., M. Verlaan, E. Kalkhoven & A. Zantema: Cascade of distinct histone modifications during collagenase gene activation. Mol Cell Biol, 23, 1808-1816 (2003)
37. Ma, Z., R. C. Shah, M. J. Chang & E. N. Benveniste: Coordination of cell signaling, chromatin remodeling, histone modifications, and regulator recruitment in human matrix metalloproteinase 9 gene transcription. Mol Cell Biol, 24, 5496-5509 (2004)
38. Young, D. A., R. L. Lakey, C. J. Pennington, D. Jones, L. Kevorkian, D. R. Edwards, T. E. Cawston & I. M. Clark: Histone deacetylase inhibitors modulate metalloproteinase gene expression in chondrocytes and block cartilage resorption. Arthritis Res Ther, 7, R503-512 (2005)
39. Young, D. A., O. Billingham, C. L. Sampieri, D. R. Edwards & I. M. Clark: Differential effects of histone deacetylase inhibitors on phorbol ester- and TGF-betal induced murine tissue inhibitor of metalloproteinases-1 gene expression. FEBS J, 272, 1912-1926 (2005)
40. Weiss, C., S. Schneider, E. F. Wagner, X. Zhang, E. Seto & D. Bohmann: JNK phosphorylation relieves HDAC3-dependent suppression of the transcriptional activity of c-Jun. EMBO J, 22, 3686-3695 (2003)
41. Yamaguchi, K., A. Lantowski, A. J. Dannenberg & K. Subbaramaiah: Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J Biol Chem, 280, 32569-32577 (2005)
42. Shankaranarayanan, P., P. Chaitidis, H. Kuhn & S. Nigam: Acetylation by histone acetyltransferase CREB-binding protein/p300 of STAT6 is required for transcriptional activation of the 15-lipoxygenase-1 gene. J Biol Chem, 276, 42753-42760 (2001)
43. Chang, H. M., M. Paulson, M. Holko, C. M. Rice, B. R. Williams, I. Marie & D. E. Levy: Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA, 101, 9578-9583 (2004)
44. Genin, P., P. Morin & A. Civas: Impairment of interferon-induced IRF-7 gene expression due to inhibition of ISGF3 formation by trichostatin A. J Virol, 77, 7113-7119 (2003)
45. Rascle, A., J. A. Johnston & B. Amati: Deacetylase activity is required for recruitment of the basal transcription machinery and transactivation by STAT5. Mol Cell Biol, 23, 4162-4173 (2003)
46. Nusinzon, I. & C. M. Horvath: Interferon-stimulated transcription and innate antiviral immunity require deacetylase activity and histone deacetylase 1. Proc Natl Acad Sci USA, 100, 14742-14747 (2003)
47. Sakamoto, S., R. Potla & A. C. Larner: Histone deacetylase activity is required to recruit RNA polymerase II to the promoters of selected interferon-stimulated early response genes. J Biol Chem, 279, 40362-40367 (2004)
48. Vincenti, M. P. & C. E. Brinckerhoff: Transcriptional regulation of collagenase (MMP-1, MMP-13) genes in arthritis: integration of complex signaling pathways for the recruitment of gene-specific transcription factors. Arthritis Res, 4, 157-164 (2002)
49. Kiernan, R., V. Bres, R. W. Ng, M. P. Coudart, S. El Messaoudi, C. Sardet, D. Y. Jin, S. Emiliani & M. Benkirane: Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem, 278, 2758-2766 (2003)
50. Chen, L., W. Fischle, E. Verdin & W. C. Greene: Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science, 293, 1653-1657 (2001)
51. Chen, L. F., Y. Mu & W. C. Greene: Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J, 21, 6539-6548 (2002)
52. Gronroos, E., U. Hellman, C. H. Heldin & J. Ericsson: Control of Smad7 stability by competition between acetylation and ubiquitination. Mol Cell, 10, 483-493 (2002)
53. Simonsson, M., C. H. Heldin, J. Ericsson & E. Gronroos: The balance between acetylation and deacetylation controls Smad7 stability. J Biol Chem, 280, 21797-21803 (2005)
54. Braun, H., R. Koop, A. Ertmer, S. Nacht & G. Suske: Transcription factor Sp3 is regulated by acetylation. Nucleic Acids Res, 29, 4994-5000 (2001)
55. Ammanamanchi, S., J. W. Freeman & M. G. Brattain: Acetylated sp3 is a transcriptional activator. J Biol Chem, 278, 35775-35780 (2003)
56. Huang, W., S. Zhao, S. Ammanamanchi, M. Brattain, K. Venkatasubbarao & J. W. Freeman: Trichostatin A induces transforming growth factor beta type II receptor promoter activity and acetylation of Sp1 by recruitment of PCAF/p300 to a Sp1.NF-Y complex. J Biol Chem, 280, 10047-10054 (2005)
57. Czuwara-Ladykowska, J., V. I. Sementchenko, D. K. Watson & M. Trojanowska: Ets1 is an effector of the transforming growth factor beta (TGF-beta) signaling pathway and an antagonist of the profibrotic effects of TGF-beta. J Biol Chem, 277, 20399-20408 (2002)
58. Yang, S. H. & A. D. Sharrocks: SUMO promotes HDAC-mediated transcriptional repression. Mol Cell, 13, 611-617 (2004)